Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance shows reduced operating expenses and net loss, but there's a significant cash flow risk due to outstanding exchangeable notes and deferred milestone payments. The Q&A reveals strategic uncertainties and limited clarity on future partnerships. The lack of European patents and the need for additional studies in key markets like China and Japan further complicate the outlook. Despite a promising label for ORLYNVAH, these factors balance out, suggesting a neutral stock price movement over the next two weeks.
Key Financial Performance
Total Operating Expenses $4.9 million in Q3 2024, down from $16.7 million in Q3 2023, a decrease of $11.8 million due to lower R&D expenses related to the completion of the REASSURE trial.
Research and Development Expenses $3.1 million in Q3 2024, down from $14.9 million in Q3 2023, a decrease of $11.8 million primarily due to higher costs incurred in 2023 to support the REASSURE trial.
General and Administrative Expenses $1.8 million in Q3 2024, flat compared to $1.8 million in Q3 2023.
Net Loss (GAAP) $6.1 million in Q3 2024, compared to $3.9 million in Q3 2023, an increase of $2.2 million.
Net Loss (Non-GAAP) $4.8 million in Q3 2024, compared to $15.7 million in Q3 2023, a decrease of $10.9 million primarily due to lower R&D expenses related to the REASSURE trial.
Cash, Cash Equivalents and Short-term Investments $14.5 million at the end of September 2024.
Exchangeable Notes Outstanding Approximately $11.1 million of exchangeable notes outstanding, which can be exchanged for approximately 1.9 million shares.
Regulatory Milestone Payment to Pfizer $20 million milestone payment owed upon approval of ORLYNVAH, deferred for two years under a promissory note.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product: FDA approval for ORLYNVAH, an oral sulopenem product for treating uncomplicated urinary tract infections.
Market Potential: ORLYNVAH is the first U.S. approved oral product in the penem class, addressing a market lacking new oral treatments for 25 years.
Market Exclusivity: ORLYNVAH has 10 years of market exclusivity under the GAIN Act, extending to October 25, 2034.
Patent Protection: U.S. patent portfolio protects oral sulopenem until 2039, with patents covering method of use and composition.
Operational Efficiency: Total operating expenses decreased to $4.9 million in Q3 2024 from $16.7 million in Q3 2023.
R&D Expense Reduction: R&D costs dropped to $3.1 million in Q3 2024 from $14.9 million in Q3 2023, primarily due to lower costs related to the REASSURE trial.
Strategic Shift: Focus on commercialization plans for ORLYNVAH, with potential partnerships or direct sales.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Strategic Transaction Risks: Risks and uncertainties concerning the outcome, impact, effects and results of evaluation of strategic alternatives, including the terms, timing, structure, value benefits and costs of any strategic transaction.
Commercialization Risks: Challenges in successfully preparing and implementing commercialization plans for ORLYNVAH with a commercial partner or directly if a strategic transaction is not completed.
Market Acceptance Risks: Uncertainties regarding the market opportunity for ORLYNVAH and its potential market acceptance.
Cash Flow Risks: Concerns about the accuracy of expectations regarding how far into the future cash on hand will fund ongoing operations.
NASDAQ Listing Risks: The ability to maintain listing on the NASDAQ capital market.
Regulatory Milestone Payment: Upon approval of ORLYNVAH, a $20 million regulatory milestone payment owed to Pfizer, which has been deferred for two years.
Exchangeable Notes: Obligation to pay $11.1 million plus accrued interest on exchangeable notes in January 2025 if not exchanged.
Antimicrobial Resistance: The growing health crisis of rising antimicrobial resistance, which creates challenges for treating physicians.
Patient Risk Groups: At-risk patient groups may have limited or no alternative treatment options, increasing the urgency for effective solutions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Approval of ORLYNVAH: Received FDA approval for ORLYNVAH, an oral sulopenem product for treating uncomplicated urinary tract infections.
Market Exclusivity: ORLYNVAH has market exclusivity for 10 years from the date of approval, until October 25, 2034, under the GAIN Act.
Patent Protection: U.S. patent portfolio provides protection for oral sulopenem into 2039, covering method of use and composition of matter.
Target Patient Groups: Identified at-risk patient groups for ORLYNVAH, including women over 65, those with diabetes, and patients with recurrent infections.
Cash Runway: Expect to fund operations into 2025, including repayment of exchangeable notes due January 31, 2025.
Operating Expenses: Total operating expenses were $4.9 million in Q3 2024, down from $16.7 million in Q3 2023.
Net Loss: Net loss on a GAAP basis was $6.1 million for Q3 2024, compared to $3.9 million in Q3 2023.
Non-GAAP Net Loss: Non-GAAP net loss was $4.8 million in Q3 2024, down from $15.7 million in Q3 2023.
Cash Position: As of September 2024, cash and equivalents were $14.5 million, expected to fund operations into 2025.
Exchangeable Notes: Approximately $11.1 million of exchangeable notes outstanding, due January 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Exchangeable Notes: As of November 4, 2024, we had approximately $11.1 million of exchangeable notes outstanding, which can be exchanged at the option of the noteholder for approximately 1.9 million shares.
Regulatory Milestone Payment: Upon approval of ORLYNVAH, we owed Pfizer a $20 million regulatory milestone, which has been deferred for two years for issuance of a promissory note.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss how far out the sulopenem portfolio provide coverage for both in the U.S. and maybe in Europe as well?
A:The GAIN Act provides the incremental five years of market exclusivity, totaling 10 years from the date of approval, extending to 2034. The latest patent expiration dates are into 2039 in the U.S. and similar in other territories, but we do not yet have European patents granted.
Q:Does the ORLYNVAH label meet your internal expectations in terms of how broad it is and also the restrictions anticipated?
A:We were very pleased with the label, which we believe is appropriate for patients at risk. There are no unusual restrictions or post-marketing requirements beyond standard pediatric studies and surveillance.
Q:Can you discuss your impression so far on your discussions on the strategic options to date?
A:We have renewed our process with our financial adviser for outreach to companies to achieve a strategic transaction.
Q:Would potential partners need another trial in EU, China, Japan or other regions to extend approvals ex-U.S.?
A:In the EU, you can file with the current data package without needing another study. However, in China and Japan, an additional study would be required.
Q:Do you think the data from the complicated UTI trial could make the drug more attractive to potential partners?
A:There is interest in complicated UTI as a step-down drug. To get a formal approved indication, only one additional study would be needed, and we believe we have a good understanding of what that study would entail.
Q:Review of Unclear Management Responses
A:Management did not provide a direct answer regarding the specifics of the strategic options discussions, only stating that the process has been renewed without further detail.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
China Japan
EU
FDA Orange
HC Wainwright
Iterum
ORLYNVAH FDA
Orange Book
ability
agent
approval ORLYNVAH
cash
company
date note
drug
effort
end
infection market
interest
label
loss
market exclusivity
partner
patent ORLYNVAH
portfolio
protection
question
repayment date
resistance rate
restriction
study
sulopenem
term
territory
treatment option
understanding
year
ITRM Transcript
Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call reveals a concerning financial performance with a widening net loss and increased expenses due to commercialization activities. The Q&A highlighted uncertainties about payer coverage and formulary approvals, which are crucial for future sales. While there is positive physician feedback, the limited current coverage and the lack of detailed guidance on key metrics contribute to a negative outlook. The stock is likely to react negatively in the short term due to these uncertainties and financial pressures.
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call presents a mixed picture. Financial performance shows improvement with reduced losses and operating expenses, which is positive. However, the lack of clarity on partnerships and the need for capital raising post-launch are concerning. The absence of a share repurchase program and competition risks further dampen sentiment. Despite projected sales potential, uncertainties in commercialization plans and strategic alternatives evaluation create a balanced outlook, suggesting a neutral stock price movement in the short term.
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges
Unknown2-7
The earnings call highlights significant risks, including going concern issues, capital raising challenges, and uncertainties about market acceptance. Despite reduced operating expenses and net losses, the company's financial health remains precarious due to a deferred $20 million payment to Pfizer accruing interest. The lack of clear guidance on strategic partnerships further exacerbates concerns. The Q&A section reveals management's evasiveness, which may increase investor apprehension. Given these factors, the stock price is likely to face a negative reaction over the next two weeks.
Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
Unknown11-14
The earnings call presents a mixed outlook. Financial performance shows reduced operating expenses and net loss, but there's a significant cash flow risk due to outstanding exchangeable notes and deferred milestone payments. The Q&A reveals strategic uncertainties and limited clarity on future partnerships. The lack of European patents and the need for additional studies in key markets like China and Japan further complicate the outlook. Despite a promising label for ORLYNVAH, these factors balance out, suggesting a neutral stock price movement over the next two weeks.
ITRM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
